Anixa Biosciences is trading at $3.34, up 5.13% in after-hours trading; no company-specific announcement explaining the move was identified.

  • The latest company release found was dated November 4 and concerned a presentation of its ovarian cancer CAR-T trial at an upcoming medical congress.
  • The regular-session close was $3.17 on November 6, according to the supplied price context.
  • Broader-market signals were mixed, so available evidence does not establish a market-wide explanation for the after-hours gain.